AVTX · Avalo Therapeutics Inc
United States · RS rating 6 · As of 2026-11-03
| Price | 7.25 USD |
|---|---|
| 1-day change | -1.0% |
| RS rating (overall / 1M / 3M / 12M) | 6 / 4 / 5 / 17 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 1 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +15.3% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +68.3% |
| Market cap (USD) | $336.1M |